Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht...
-
Upload
stephanie-leblanc -
Category
Documents
-
view
225 -
download
0
Transcript of Universitätsklinikum Frankfurt am Main R. Knecht Universitätsklinikum Frankfurt am Main R. Knecht...
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy TPF Induction chemotherapy TPF 3 Cycles3 Cycles
Docetaxel 75mg/mDocetaxel 75mg/m22 d1 d1
Cisplatin 100mg/mCisplatin 100mg/m2 2 d1d1
5-FU 1000mg/m5-FU 1000mg/m2 2 d1-4d1-4
Induction chemotherapy TPF Induction chemotherapy TPF 3 Cycles3 Cycles
Docetaxel 75mg/mDocetaxel 75mg/m22 d1 d1
Cisplatin 100mg/mCisplatin 100mg/m2 2 d1d1
5-FU 1000mg/m5-FU 1000mg/m2 2 d1-4d1-4
RadiochemotherapyRadiochemotherapy 70 Gy + Cisplatin 100 mg /m70 Gy + Cisplatin 100 mg /m22 d1, 22, 43 d1, 22, 43
RadiochemotherapyRadiochemotherapy 70 Gy + Cisplatin 100 mg /m70 Gy + Cisplatin 100 mg /m22 d1, 22, 43 d1, 22, 43
Laryngoprotect-StudyLaryngoprotect-StudyR. Knecht et al.R. Knecht et al.
Laryngoprotect-StudyLaryngoprotect-StudyR. Knecht et al.R. Knecht et al.
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Regions and stages in %Regions and stages in %Regions and stages in %Regions and stages in %
55%55%
24%24%
21%21%
T/NT/N
4
4
13
21
2
3
3
8
NN11 NN22 NN33
2525
3434
2525
3434
2
3
-
5
TT22
TT33
TT44
15
35
50
100
NN00
Stage IIStage II Stage IIIStage III Stage IVStage IV
7
66
n=103n=103
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Toxicity Toxicity (WHO Grad III / IV)(WHO Grad III / IV)Toxicity Toxicity (WHO Grad III / IV)(WHO Grad III / IV)
RenalRenal 25%25%
Afebrile Neutropenia Afebrile Neutropenia 95%95%
Nausea/VomitingNausea/Vomiting 25%25%
Mucositis Mucositis 10%10%
Sensory NeuropathySensory Neuropathy 10%10%
4%4%
47%47%
20%20%
43%43%
5%5%
InductionInductionchemotherapychemotherapy
Radio-Radio-chemotherapychemotherapy
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
SupraglottisSupraglottis
GlottisGlottis
Hypopharynx Hypopharynx
SupraglottisSupraglottis
GlottisGlottis
Hypopharynx Hypopharynx
RRRRRRRR
76%76%
73%73%
92%92%
79%79%
76%76%
73%73%
92%92%
79%79%
41%41%
53%53%
54%54%
47%47%
41%41%
53%53%
54%54%
47%47%
CRCRCRCR
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpost
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
prae
S. A., T3N3M0
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postprae
B. W., T2N1M0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
prae
B. W., T2N1M0post
ResultsResultsafter TPF - Polychemotherapy(3 Cycles)after TPF - Polychemotherapy(3 Cycles)
ResultsResultsafter TPF - Polychemotherapy(3 Cycles)after TPF - Polychemotherapy(3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpostpraeprae
M. B., T2N1M0M. B., T2N1M0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
postpostprae prae
B. H., T2N2bM0B. H., T2N2bM0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpost
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
prae prae
G. H., T2N2bM0G. H., T2N2bM0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
postpost
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
Zur Anzeige wird der QuickTime™ Dekompressor „YUV420 codec“
benötigt.
prae prae
J. H., T2N2bM0J. H., T2N2bM0
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
ResultsResultsafter TPF - Polychemotherapy (3 Cycles)after TPF - Polychemotherapy (3 Cycles)
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Laryngoprotect n = 103
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
74% 74% 75%75%
2% 2% 93%93%
74% 74% 75%75%
2% 2% 93%93%
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
2 years
ResultsResultsHypopharynxHypopharynxResultsResultsHypopharynxHypopharynx
Knecht R . et al. Knecht R . et al. (2004)(2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induktion chemotherapy Induktion chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induktion chemotherapy Induktion chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
2 years
Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103
91% 91% 85%85%
0% 0% 94%94%
91% 91% 85%85%
0% 0% 94%94%
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
ResultsResultsLarynxLarynx
ResultsResultsLarynxLarynx
Knecht R . et al. Knecht R . et al. (2004)(2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
2 years
Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103Laryngoprotect n = 103
91% 91% 85%85%
0% 0% 94%94%
91% 91% 85%85%
0% 0% 94%94%
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
Larynx preservationLarynx preservationDisease free surv.Disease free surv.Distant metastasisDistant metastasisSurvivalSurvival
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
ResultsResultsLarynxLarynx
ResultsResultsLarynxLarynx
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RTOG 91-11 n = 172
88% 88% 61%61%
8% 8% 74%74%
88% 88% 61%61%
8% 8% 74%74%
Knecht R . et al. Knecht R . et al. (2004)(2004) JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559JOURNAL OF CLINICAL ONCOLOGY 22 (14): 502S-502S 5559
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Laryngoprotect 2Laryngoprotect 2Laryngoprotect 2Laryngoprotect 2
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
Induction chemotherapy Induction chemotherapy 3 Cycles3 Cycles
Cisplatin (100mg/mCisplatin (100mg/m22) ) 5 Fluorouracil (4000mg/m5 Fluorouracil (4000mg/m22))
Docetaxel (75mg/mDocetaxel (75mg/m22))
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
RadiochemotherapyRadiochemotherapy (70Gy)
Cisplatin (3x 100mg/m2)
22
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
UniversitätsklinikumUniversitätsklinikumFrankfurt am MainFrankfurt am MainR. KnechtR. Knecht
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Radiochemotherapy Radiochemotherapy 70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m2 2 total)total)
Radiochemotherapy Radiochemotherapy 70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m70 Gy (2 Gy/d; 5x/week) Cisplatin, (300mg/m2 2 total)total)
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Cetuximab (400 mg d1; 250mg ab d8 wöchtl)(400 mg d1; 250mg ab d8 wöchtl)
Induction chemotherapy TPF 3Cycles Docetaxel 75mg/m2 d1Cisplatin 100mg/m2 d15-FU 1000mg/m2 d1-4
Cetuximab (400 mg d1; 250mg ab d8 wöchtl)(400 mg d1; 250mg ab d8 wöchtl)
International principal investigator: R. KnechtInternational principal investigator: R. KnechtInternational principal investigator: R. KnechtInternational principal investigator: R. Knecht
Stage III/IVStage III/IVStage III/IVStage III/IV
EGFR-Antibody EGFR-Antibody Neoadjuvant Primary TherapyNeoadjuvant Primary Therapy EGFR-Antibody EGFR-Antibody
Neoadjuvant Primary TherapyNeoadjuvant Primary Therapy